

## Amendments to the Claims

This listing of claims will replace all prior versions and listings of claims in the application:

### Listing of Claims

1. (Currently amended) A method of protecting an immune-compromised human from at least one of *Staphylococcal* and *Enterococcal* bacterial infection, comprising administering a vaccine comprising a glycoconjugate of a polysaccharide or glycopeptide bacterial surface antigen and an immunocarrier to an immune-compromised human, wherein said vaccine comprises:
  - (a) glycoconjugates of both Type 5 and Type 8 polysaccharide antigens of *S. aureus*;
  - (b) ~~a glycoconjugate of a negatively charged *Staphylococcal* polysaccharide antigen that comprises  $\beta$  linked hexosamine as a major carbohydrate component and contains no O acetyl groups;~~
  - (c) ~~a glycoconjugate of *Staphylococcal* glycopeptide antigen that comprises amino acids and a N acetylated hexosamine in an  $\alpha$  configuration, that contains no O acetyl groups, and that contains no hexose;~~
  - (d) ~~a glycoconjugate of an acidic *Staphylococcal* polysaccharide antigen that is obtained from an isolate of *S. epidermidis* that agglutinates antisera to ATCC 55254;~~
  - (e) ~~a glycoconjugate of an *E. faecalis* antigen that comprises 2 acetamido 2 deoxy glucose and rhamnose in a 1:2 molar ratio;~~
  - (f) ~~a glycoconjugate of an *E. faecalis* antigen that comprises a trisaccharide repeat which comprises a 6 deoxy sugar;~~
  - (g) ~~a glycoconjugate of an *E. faecium* antigen that comprises 2 acetamido 2 deoxy galactose and galactose in a 2:1 molar ratio;~~
  - (h) ~~a glycoconjugate of an *E. faecium* antigen that reacts with antibodies to ATCC 202016;~~
  - or
  - (i) ~~a glycoconjugate of an *E. faecium* antigen that reacts with antibodies to ATCC 202017.~~

Claims 2-13 (canceled)

14. (Currently Amended) A method according to claim 1, wherein said immune-compromised human is selected from the group consisting of end stage renal disease (ESRD) patients; cancer patients on immunosuppressive therapy, ~~AIDS patients~~, diabetic patients, ~~neonates~~, the elderly in extended care facilities, ~~patients with autoimmune disease on immunosuppressive therapy~~, transplant patients, patients with invasive surgical procedures, ~~burn patients~~ and other patients in acute care settings.

15. (Original) A method according to claim 1, wherein said immune-compromised human suffers from end stage renal disease.

16. (Original) A method according to claim 1, wherein said immune-compromised human is a neonate.

17. (Original) A method according to claim 1, wherein said immunocarrier is diphtheria toxoid, tetanus toxoid, recombinantly produced, genetically detoxified variants thereof or a recombinantly-produced, non-toxic-mutant of *Pseudomonas aeruginosa* exotoxin A or *Staphylococcal* exotoxin or toxoid.

18. (Original) A method according to claim 1, wherein said vaccine additionally comprises an adjuvant or immuostimulant.

19. (Original) A method according to claim 1, wherein said vaccine additionally comprises a  $\beta$ -glucan or granulocyte colony stimulating factor.